Loading…

Handling the different requirements for commercial and investigational MNC collections by apheresis

With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively str...

Full description

Saved in:
Bibliographic Details
Published in:Cytotherapy (Oxford, England) England), 2024-08, Vol.26 (8), p.948-953
Main Authors: Bobr, Aleh, Roberts, Timothy, Koepsell, Scott, Williams, Shelly M., Schwartz, Joseph
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953
container_end_page 953
container_issue 8
container_start_page 948
container_title Cytotherapy (Oxford, England)
container_volume 26
creator Bobr, Aleh
Roberts, Timothy
Koepsell, Scott
Williams, Shelly M.
Schwartz, Joseph
description With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies. Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue. Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested. The current recommendations from multiple sources were reviewed in discussion.
doi_str_mv 10.1016/j.jcyt.2024.04.001
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3050942543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1465324924005991</els_id><sourcerecordid>3050942543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</originalsourceid><addsrcrecordid>eNp9UE1rGzEUFKElcd3-gR6Kjrms8ySttLvQSzFpE3DbS3IWkvbJltkPR1oH_O-jxW6OhQdvGGaG94aQrwxWDJi626_27jStOPByBXmAXZEFK6uq4FKpDzNWshC8bG7Ip5T2ABzqWl6TG1FXIJhUC-IezNB2YdjSaYe0Dd5jxGGiEV-OIWKfcaJ-jNSNfY_RBdPR7KBheMU0ha2Zwjhk7vefdZZ0HbqZSNSeqDnsclYK6TP56E2X8MtlL8nzz_un9UOx-fvrcf1jUzgB1VQ4DrZ2jbWWM2Vaxb1XGcq6tg2XWIIxTDSNASe8rH2mpeKV9NYab9pGiiW5Pece4vhyzOfpPiSHXWcGHI9JC5DQlFyWIkv5WerimFJErw8x9CaeNAM9l6v3ei5Xz-VqyAMsm75d8o-2x_bd8q_NLPh-FmD-8jVg1MkFHBy2uUo36XYM_8t_A9KTjRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3050942543</pqid></control><display><type>article</type><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><source>ScienceDirect Journals</source><creator>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</creator><creatorcontrib>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</creatorcontrib><description>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies. Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue. Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested. The current recommendations from multiple sources were reviewed in discussion.</description><identifier>ISSN: 1465-3249</identifier><identifier>ISSN: 1477-2566</identifier><identifier>EISSN: 1477-2566</identifier><identifier>DOI: 10.1016/j.jcyt.2024.04.001</identifier><identifier>PMID: 38703156</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>apheresis ; MNC collection ; regulatory requirements</subject><ispartof>Cytotherapy (Oxford, England), 2024-08, Vol.26 (8), p.948-953</ispartof><rights>2024 International Society for Cell &amp; Gene Therapy</rights><rights>Copyright © 2024 International Society for Cell &amp; Gene Therapy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</cites><orcidid>0000-0002-0398-2359 ; 0000-0003-1597-8071</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1465324924005991$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45779</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38703156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bobr, Aleh</creatorcontrib><creatorcontrib>Roberts, Timothy</creatorcontrib><creatorcontrib>Koepsell, Scott</creatorcontrib><creatorcontrib>Williams, Shelly M.</creatorcontrib><creatorcontrib>Schwartz, Joseph</creatorcontrib><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><title>Cytotherapy (Oxford, England)</title><addtitle>Cytotherapy</addtitle><description>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies. Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue. Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested. The current recommendations from multiple sources were reviewed in discussion.</description><subject>apheresis</subject><subject>MNC collection</subject><subject>regulatory requirements</subject><issn>1465-3249</issn><issn>1477-2566</issn><issn>1477-2566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UE1rGzEUFKElcd3-gR6Kjrms8ySttLvQSzFpE3DbS3IWkvbJltkPR1oH_O-jxW6OhQdvGGaG94aQrwxWDJi626_27jStOPByBXmAXZEFK6uq4FKpDzNWshC8bG7Ip5T2ABzqWl6TG1FXIJhUC-IezNB2YdjSaYe0Dd5jxGGiEV-OIWKfcaJ-jNSNfY_RBdPR7KBheMU0ha2Zwjhk7vefdZZ0HbqZSNSeqDnsclYK6TP56E2X8MtlL8nzz_un9UOx-fvrcf1jUzgB1VQ4DrZ2jbWWM2Vaxb1XGcq6tg2XWIIxTDSNASe8rH2mpeKV9NYab9pGiiW5Pece4vhyzOfpPiSHXWcGHI9JC5DQlFyWIkv5WerimFJErw8x9CaeNAM9l6v3ei5Xz-VqyAMsm75d8o-2x_bd8q_NLPh-FmD-8jVg1MkFHBy2uUo36XYM_8t_A9KTjRk</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Bobr, Aleh</creator><creator>Roberts, Timothy</creator><creator>Koepsell, Scott</creator><creator>Williams, Shelly M.</creator><creator>Schwartz, Joseph</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0398-2359</orcidid><orcidid>https://orcid.org/0000-0003-1597-8071</orcidid></search><sort><creationdate>20240801</creationdate><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><author>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>apheresis</topic><topic>MNC collection</topic><topic>regulatory requirements</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bobr, Aleh</creatorcontrib><creatorcontrib>Roberts, Timothy</creatorcontrib><creatorcontrib>Koepsell, Scott</creatorcontrib><creatorcontrib>Williams, Shelly M.</creatorcontrib><creatorcontrib>Schwartz, Joseph</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cytotherapy (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bobr, Aleh</au><au>Roberts, Timothy</au><au>Koepsell, Scott</au><au>Williams, Shelly M.</au><au>Schwartz, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Handling the different requirements for commercial and investigational MNC collections by apheresis</atitle><jtitle>Cytotherapy (Oxford, England)</jtitle><addtitle>Cytotherapy</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>26</volume><issue>8</issue><spage>948</spage><epage>953</epage><pages>948-953</pages><issn>1465-3249</issn><issn>1477-2566</issn><eissn>1477-2566</eissn><abstract>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies. Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue. Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested. The current recommendations from multiple sources were reviewed in discussion.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>38703156</pmid><doi>10.1016/j.jcyt.2024.04.001</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0398-2359</orcidid><orcidid>https://orcid.org/0000-0003-1597-8071</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1465-3249
ispartof Cytotherapy (Oxford, England), 2024-08, Vol.26 (8), p.948-953
issn 1465-3249
1477-2566
1477-2566
language eng
recordid cdi_proquest_miscellaneous_3050942543
source ScienceDirect Journals
subjects apheresis
MNC collection
regulatory requirements
title Handling the different requirements for commercial and investigational MNC collections by apheresis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Handling%20the%20different%20requirements%20for%20commercial%20and%20investigational%20MNC%20collections%20by%20apheresis&rft.jtitle=Cytotherapy%20(Oxford,%20England)&rft.au=Bobr,%20Aleh&rft.date=2024-08-01&rft.volume=26&rft.issue=8&rft.spage=948&rft.epage=953&rft.pages=948-953&rft.issn=1465-3249&rft.eissn=1477-2566&rft_id=info:doi/10.1016/j.jcyt.2024.04.001&rft_dat=%3Cproquest_cross%3E3050942543%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3050942543&rft_id=info:pmid/38703156&rfr_iscdi=true